[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

BE2015C078I2 - - Google Patents

Download PDF

Info

Publication number
BE2015C078I2
BE2015C078I2 BE2015C078C BE2015C078C BE2015C078I2 BE 2015C078 I2 BE2015C078 I2 BE 2015C078I2 BE 2015C078 C BE2015C078 C BE 2015C078C BE 2015C078 C BE2015C078 C BE 2015C078C BE 2015C078 I2 BE2015C078 I2 BE 2015C078I2
Authority
BE
Belgium
Application number
BE2015C078C
Other languages
Dutch (nl)
Original Assignee
Omeros Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=31188639&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BE2015C078(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Omeros Corp filed Critical Omeros Corp
Publication of BE2015C078I2 publication Critical patent/BE2015C078I2/nl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/08—Mydriatics or cycloplegics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Surgery (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
BE2015C078C 2002-07-30 2015-12-18 BE2015C078I2 (xx)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39989902P 2002-07-30 2002-07-30
PCT/US2003/023871 WO2004010894A2 (en) 2002-07-30 2003-07-30 Ophthalmologic irrigation solutions and method

Publications (1)

Publication Number Publication Date
BE2015C078I2 true BE2015C078I2 (xx) 2022-08-09

Family

ID=31188639

Family Applications (1)

Application Number Title Priority Date Filing Date
BE2015C078C BE2015C078I2 (xx) 2002-07-30 2015-12-18

Country Status (18)

Country Link
US (10) US20040072809A1 (xx)
EP (1) EP1534313B1 (xx)
JP (11) JP2006504661A (xx)
CN (3) CN1684701B (xx)
AU (2) AU2003261304A1 (xx)
BE (1) BE2015C078I2 (xx)
CA (2) CA2866848C (xx)
CY (1) CY2015055I2 (xx)
DK (1) DK1534313T3 (xx)
ES (1) ES2397574T3 (xx)
FR (1) FR15C0090I2 (xx)
HK (1) HK1081455A1 (xx)
HU (1) HUS1500069I1 (xx)
LU (1) LU92923I2 (xx)
NL (1) NL300784I2 (xx)
PT (1) PT1534313E (xx)
SI (1) SI1534313T1 (xx)
WO (1) WO2004010894A2 (xx)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004010894A2 (en) 2002-07-30 2004-02-05 Omeros Corporation Ophthalmologic irrigation solutions and method
US8372814B2 (en) * 2004-06-07 2013-02-12 Ista Pharmaceuticals, Inc. Ophthalmic formulations and uses thereof
US8748402B2 (en) 2004-06-07 2014-06-10 Bausch & Lomb Pharma Holdings Corp. Ophthalmic formulations and uses thereof
CA2573144C (en) 2004-06-10 2014-07-22 Omeros Corporation Methods for treating conditions associated with masp-2 dependent complement activation
US7919094B2 (en) 2004-06-10 2011-04-05 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
ATE529133T1 (de) * 2004-08-18 2011-11-15 Medrx Co Ltd Topisches präparat
FR2882930B1 (fr) * 2005-03-09 2009-03-27 Walid Katib Nouvelles compositions ophtalmologiques et leur mode d'utilisation
US20070048389A1 (en) * 2005-08-26 2007-03-01 Fu-Pao Tsao Stabilized and preserved ketotifen ophthalmic compositions
US20080153818A1 (en) * 2006-12-21 2008-06-26 Bingaman David P Methods for preventing inflammation during surgery
CN101534794A (zh) * 2006-12-22 2009-09-16 希格马托制药工业公司 用于递送眼科用药物的凝胶
CA2688547A1 (en) * 2007-06-05 2008-12-11 Xenon Pharmaceuticals, Inc. Aromatic and heteroaromatic compounds useful in treating iron disorders
CN101347620B (zh) * 2007-07-20 2012-04-25 天津药业研究院有限公司 一种药物组合物及其在制备治疗青光眼的药物中的应用
EP2363147B1 (en) 2008-10-30 2016-02-24 National University Corporation Okayama University Composition for local anesthesia
WO2010053487A1 (en) * 2008-11-07 2010-05-14 Cydex Pharmaceuticals, Inc. Composition containing sulfoalkyl ether cyclodextrin and latanoprost
CA2754996A1 (en) * 2009-03-17 2010-09-23 Aciex Therapeutics, Inc. Ophthalmic formulations of ketotifen and methods of use
GB0915319D0 (en) * 2009-09-03 2009-10-07 Sharma Anant Combination medicament
BR112012008970A2 (pt) 2009-10-16 2019-12-10 Omeros Corp uso de uma composição, e, composição
EP2675455A4 (en) * 2011-02-18 2014-07-16 M S Appasamy Associates OPHTHALMIC COMPOSITION FOR DILATING PUPILS
ITPA20110004A1 (it) * 2011-02-23 2012-08-24 Francesco Paolo Montalto Iniezione intracamerulare per anestesia e dilatazione pupillare (midriasi).
US9644035B2 (en) 2011-04-08 2017-05-09 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
KR20210021101A (ko) 2011-04-08 2021-02-24 유니버시티 오브 레스터 Ｍａｓｐ-2 의존적 보체 활성화와 관련된 질병을 치료하는 방법
AU2013201465B2 (en) * 2012-10-24 2016-03-03 Rayner Surgical (Ireland) Limited Stable preservative-free mydriatic and anti-inflammatory solutions for injection
US9504691B2 (en) * 2012-12-06 2016-11-29 Alcon Research, Ltd. Finafloxacin suspension compositions
RU2525512C1 (ru) * 2013-03-28 2014-08-20 федеральное государственное бюджетное учреждение "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова" Министерства здравоохранения Российской Федерации Способ медикаментозного расширения ригидного зрачка перед проведением факоэмульсификации
CA2911298C (en) * 2013-05-06 2019-09-17 Kaohsiung Chang Gung Memorial Hospital A pharmaceutical composition comprising atropine and nsaid for treating myopia
RU2529787C1 (ru) * 2013-06-03 2014-09-27 федеральное государственное бюджетное учреждение "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова" Министерства здравоохранения Российской Федерации Офтальмологический ирригационный раствор
CA2920835A1 (en) 2013-08-20 2015-02-26 Anutra Medical, Inc. Syringe fill system and method
JP2016532723A (ja) * 2013-10-03 2016-10-20 インプリミス・ファーマシューティカルズ・インコーポレイテッドＩｍｐｒｉｍｉｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 眼内投与のためのエピネフリン系点眼用組成物及びその製造のための方法
EP3099304B1 (en) 2014-01-31 2024-07-17 Mayo Foundation for Medical Education and Research Chroman derivatives and their use in the treatment of glaucoma
USD750768S1 (en) 2014-06-06 2016-03-01 Anutra Medical, Inc. Fluid administration syringe
USD774182S1 (en) 2014-06-06 2016-12-13 Anutra Medical, Inc. Anesthetic delivery device
USD763433S1 (en) 2014-06-06 2016-08-09 Anutra Medical, Inc. Delivery system cassette
CN104324049A (zh) * 2014-09-26 2015-02-04 浙江天瑞药业有限公司 一种制备关节手术用平衡盐冲洗液的方法
TWI705812B (zh) * 2014-12-01 2020-10-01 奥默羅斯公司 用於抑制術後眼睛炎性病況的抗炎和散瞳前房溶液
CN104856990A (zh) * 2015-05-07 2015-08-26 武汉武药科技有限公司 去氧肾上腺素酮咯酸溶液及制备方法
CN105213418B (zh) * 2015-11-11 2019-01-22 中国人民解放军第四军医大学 一种眼科术前用复方滴眼液及其制备方法
US10220012B2 (en) * 2016-06-03 2019-03-05 Joerg H. KRUMEICH Solution for ophthalmology
US10231968B2 (en) 2016-08-01 2019-03-19 David R. Hardten Medicinal solution to be continuously or pulse-delivered to the eye for treating ophthalmological conditions/maladies
WO2018039420A1 (en) 2016-08-25 2018-03-01 Imprimis Pharmaceuticals, Inc. Epinephrine-based ophthalmic compositions for intraocular administration and methods for fabricating thereof
CA3035561A1 (en) * 2016-09-02 2018-03-08 Christopher J. Soares Use of cgrp receptor antagonists in neuroprotection and neurological disorders
US20180318319A1 (en) 2017-05-04 2018-11-08 Ocular Science, Inc. Compositions and Methods for Treating Eyes and Methods of Preparation
CN107137713A (zh) * 2017-05-12 2017-09-08 浙江工贸职业技术学院 一种眼科手术后用冲洗液及其制备方法
CA3066398A1 (en) * 2017-06-08 2018-12-13 Eye Therapies, Llc Low-dose brimonidine combinations and uses thereof
US11738022B2 (en) 2017-11-10 2023-08-29 The University Of Colorado, A Body Corporate Methods for inducing pupil dilation
DK3681500T3 (da) 2018-04-24 2022-06-27 Allergan Inc Anvendelse af pilocarpinhydrochlorid til behandling af presbyopi
WO2020184566A1 (ja) 2019-03-11 2020-09-17 日本放送協会 画像符号化装置、画像復号装置、及びプログラム
US11071724B2 (en) 2019-05-17 2021-07-27 Ocular Science, Inc. Compositions and methods for treating presbyopia
CN115768419A (zh) * 2020-02-07 2023-03-07 奎拉里斯生物公司 用于色满卡林前药治疗的改进方法和组合物
US11883382B2 (en) 2021-07-23 2024-01-30 Somerset Therapeutics, Llc Buffer-free ophthalmological compositions of ketorolac and phenylephrine and applications thereof
US12029729B2 (en) 2021-07-23 2024-07-09 Somerset Therapeutics, Llc Chelated, stable ophthalmological compositions of ketorolac and phenylephrine and applications thereof
WO2023048174A1 (ja) * 2021-09-22 2023-03-30 テイカ製薬株式会社 角膜疾患治療剤

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4550022A (en) 1981-10-05 1985-10-29 Alcon Laboratories, Inc. Tissue irrigating solution
JPS58126810A (ja) * 1981-12-24 1983-07-28 Kaken Pharmaceut Co Ltd 抗炎症眼科用液剤およびその製法
US4474751A (en) * 1983-05-16 1984-10-02 Merck & Co., Inc. Ophthalmic drug delivery system utilizing thermosetting gels
WO1987007141A1 (en) 1986-05-23 1987-12-03 New England Medical Center Hospitals, Inc. Method for treating glaucoma
US5212196A (en) * 1986-10-21 1993-05-18 Alcon Laboratories, Inc. Control of post-surgical intraocular pressure using clonidine derivatives
US4938970A (en) * 1987-02-06 1990-07-03 Hustead Robert E Painless electrolyte solutions
US5110493A (en) * 1987-09-11 1992-05-05 Syntex (U.S.A.) Inc. Ophthalmic NSAID formulations containing a quaternary ammonium preservative and a nonionic surfactant
US4876250A (en) * 1988-10-31 1989-10-24 Alcon Laboratories, Inc. Methods for controlling ocular hypertension with angiostatic steroids
US5051443A (en) 1988-10-12 1991-09-24 Eye Research Institute Of Retina Foundation, Inc. Method for enhancing healing of corneal endothelial wounds
US5036046A (en) 1988-10-12 1991-07-30 Eye Research Institute Of Retina Foundation, Inc. Method for enhancing healing of corneal endothelial wounds
US5371078A (en) * 1988-10-31 1994-12-06 Alcon Laboratories, Inc. Angiostatic steroids and methods and compositions for controlling ocular hypertension
US5116868A (en) * 1989-05-03 1992-05-26 The Johns Hopkins University Effective ophthalmic irrigation solution
DE69025943T2 (de) 1989-08-21 1996-09-19 Beth Israel Hospital Verwendung von Spiperone-derivate zur Immunosuppression
WO1992004008A1 (en) 1990-09-07 1992-03-19 Universidad De Alicante Composition for treating ocular pain
US5318780A (en) * 1991-10-30 1994-06-07 Mediventures Inc. Medical uses of in situ formed gels
IT1252692B (it) * 1991-11-27 1995-06-23 Zambon Spa Composizione farmaceutica per uso oftalmico contenente un antiinfiammatorio non steroideo ed un decongestionante come principi attivi
JPH07502544A (ja) * 1992-10-21 1995-03-16 アルコン　ラボラトリーズ，インコーポレイテッド 眼内組織潅注用および眼内外科処置中の瞳孔散大維持用組成物
US6117907A (en) * 1993-04-14 2000-09-12 Sher; Neal A. Topical treatment of ocular pain after corneal surgery
CA2149528A1 (en) 1993-09-29 1995-04-06 Billie M. York Compositions containing growth factors and antimetabolites
WO1995009004A1 (en) * 1993-09-29 1995-04-06 Alcon Laboratories, Inc. Compositions containing growth factors and antiplastic agents
US5624893A (en) * 1993-10-14 1997-04-29 Alcon Laboratories, Inc. Pharmaceutical compositions and methods of treatment of the cornea following laser irradiation
AU1399695A (en) 1993-12-17 1995-07-03 Alcon Laboratories, Inc. Improved intraocular irrigating solution containing non-steroidal antiinflammatory agent
US6350781B1 (en) * 1994-01-14 2002-02-26 Lee Shahinia, Jr. Method and analgesic preparations for sustained and extended corneal analgesia with subanesthetic concentrations of lidocaine
WO1995034298A1 (en) 1994-06-10 1995-12-21 Telor Ophthalmic Pharmaceuticals, Inc. Inhibition of intraoperative miosis/production of mydriasis by local anesthetics
US5523316A (en) * 1994-06-23 1996-06-04 Alcon Laboratories, Inc. Intraocular irrigating solution containing agent for controlling IOP
WO2000023072A1 (en) 1998-10-20 2000-04-27 Omeros Medical Systems, Inc. Irrigation solution containing mapk inhibitors and their use for treating pain and inflammation
ATE532530T1 (de) * 1994-12-12 2011-11-15 Omeros Corp Bespüllungslösung und deren verwendung zur perioperativen hemmung von schmerzen, entzündungen und/oder spasmen an einer gefässstruktur
WO2000023061A2 (en) 1998-10-21 2000-04-27 Omeros Medical Systems, Inc. Irrigation solution and method for inhibition of pain and inflammation
KR100517210B1 (ko) 1994-12-12 2006-06-07 오메로스 코포레이션 통증,염증및경련억제용관주용액
US7091181B2 (en) * 1994-12-12 2006-08-15 Omeros Corporation Method of inhibition of pain and inflammation during surgery comprising administration of soluble TNF receptors
JPH10510540A (ja) * 1994-12-12 1998-10-13 オメロス メディカル システムズ，インコーポレーテッド 灌注用溶液並びに疼痛、炎症及びけいれんの抑制法
US6492332B1 (en) * 1995-12-12 2002-12-10 Omeros Corporation Irrigation solution and methods for inhibition of tumor cell adhesion, pain and inflammation
WO2000023062A2 (en) 1998-10-20 2000-04-27 Omeros Medical Systems, Inc. Irrigation solution and method for inhibition of pain and inflammation
US5972326A (en) 1995-04-18 1999-10-26 Galin; Miles A. Controlled release of pharmaceuticals in the anterior chamber of the eye
US5612027A (en) * 1995-04-18 1997-03-18 Galin; Miles A. Controlled release of miotic and mydriatic drugs in the anterior chamber
US5767105A (en) * 1995-05-03 1998-06-16 Peyman; Gholam A. Ocular solution
US5798356A (en) * 1995-08-07 1998-08-25 Alcon Laboratories, Inc. Angiostatic compounds
US5849761A (en) 1995-09-12 1998-12-15 Regents Of The University Of California Peripherally active anti-hyperalgesic opiates
US6413961B1 (en) * 1995-12-12 2002-07-02 Omeros Medical Systems, Inc. Irrigation solution and method for inhibition of pain and inflammation
US6280745B1 (en) * 1997-12-23 2001-08-28 Alliance Pharmaceutical Corp. Methods and compositions for the delivery of pharmaceutical agents and/or the prevention of adhesions
EP1039818A4 (en) 1996-07-26 2001-11-07 Schein Dental Equipment Co ARMREST MECHANISM FOR DENTAL ARMCHAIRS
GB9704352D0 (en) * 1997-03-03 1997-04-23 Chiroscience Ltd Levobupivacaine and its use
WO1998043619A2 (en) * 1997-04-02 1998-10-08 The Regents Of The University Of California Method of local anesthesia
US5811446A (en) * 1997-04-18 1998-09-22 Cytos Pharmaceuticals Llc Prophylactic and therapeutic methods for ocular degenerative diseases and inflammations and histidine compositions therefor
US6034256A (en) 1997-04-21 2000-03-07 G.D. Searle & Co. Substituted benzopyran derivatives for the treatment of inflammation
US6495598B1 (en) * 1997-04-22 2002-12-17 Ophtecs Corporation Perfusate preparation for ophthalmic operation
EP0903151A1 (en) * 1997-09-22 1999-03-24 ASTA Medica Aktiengesellschaft Use of combinations comprising non-sedating antihistamines and alpha-adrenergic drugs for the topical treatment of rhinitis/conjunctivitis and cold, cold-like and/or flu symptoms
WO2000001379A1 (en) * 1998-07-01 2000-01-13 Warner-Lambert Company (-)-pseudoephedrine as a sympathomimetic drug
WO2000003705A1 (en) * 1998-07-14 2000-01-27 Alcon Laboratories, Inc. Use of 11-(3-dimethylaminopropylidene)-6,11-dihydrodibenz[b,e]oxepin-2-acetic acid for the manufacture of a medicament for treating non-allergic ophthalmic inflammatory disorders and for the prevention of ocular neovascularization
US6262066B1 (en) * 1998-07-27 2001-07-17 Schering Corporation High affinity ligands for nociceptin receptor ORL-1
US6395746B1 (en) * 1998-09-30 2002-05-28 Alcon Manufacturing, Ltd. Methods of treating ophthalmic, otic and nasal infections and attendant inflammation
US20030087962A1 (en) * 1998-10-20 2003-05-08 Omeros Corporation Arthroscopic irrigation solution and method for peripheral vasoconstriction and inhibition of pain and inflammation
EP1227807B1 (en) 1998-10-20 2005-03-30 Omeros Corporation Irrigation solution and method for inhibition of pain and inflammation
US7973068B2 (en) * 1998-10-20 2011-07-05 Omeros Corporation Arthroscopic irrigation solution and method for peripheral vasoconstriction and inhibition of pain and inflammation
DE69937070D1 (de) 1998-11-05 2007-10-18 Omeros Corp Spüllösung und verfahren zur schmerzlinderung und entzündungshemmung
US6433007B1 (en) 1998-12-17 2002-08-13 Alcon Manufacturing, Ltd. Methods for the prevention and treatment of post-surgical complications
EP1202620A1 (en) * 1999-05-14 2002-05-08 The Regents of the University of California Anti-inflammatory therapy for inflammatory mediated infection
US7273887B1 (en) * 1999-10-22 2007-09-25 Transdermatech, Inc. Topical anesthetic formulation
US6218428B1 (en) * 2000-04-28 2001-04-17 Emil Chynn Ophthalmic composition
CA2407683C (en) 2000-04-28 2010-04-13 Memorial Sloan-Kettering Cancer Center Topical anesthetic/opioid formulations and uses thereof
US20020128267A1 (en) * 2000-07-13 2002-09-12 Rebanta Bandyopadhyay Method of using COX-2 inhibitors in the treatment and prevention of ocular COX-2 mediated disorders
PE20020146A1 (es) * 2000-07-13 2002-03-31 Upjohn Co Formulacion oftalmica que comprende un inhibidor de ciclooxigenasa-2 (cox-2)
HU230383B1 (hu) * 2000-07-14 2016-03-29 Allergan, Inc Oldékonyságfokozó komponens használata brimodinin-tartarátot tartalmazó vizes készítményekben
CN1450896A (zh) * 2000-07-28 2003-10-22 印斯拜尔药品股份有限公司 用吲哚衍生物降低眼内压的方法
JP2002161032A (ja) * 2000-09-14 2002-06-04 Taisho Pharmaceut Co Ltd 粘膜適用組成物
CN1390124A (zh) * 2000-09-20 2003-01-08 永光制药有限公司 近视眼的预防、治疗药
US20020183279A1 (en) * 2001-04-18 2002-12-05 Koichiro Tanaka Pharmaceutical composition containing viscoelastic substance and medication
US20020198209A1 (en) * 2001-05-03 2002-12-26 Allergan Sales Inc. Compositions having enhanced pharmacokinetic characteristics
US20030191187A1 (en) 2002-04-01 2003-10-09 Lee Fang Yu Injectable pharmaceutical composition containing a non-steroidal anti-inflammatory drug and method for preparing the same
WO2004010894A2 (en) 2002-07-30 2004-02-05 Omeros Corporation Ophthalmologic irrigation solutions and method
MX2007007613A (es) 2004-12-22 2007-08-03 Schering Corp Formulaciones farmaceuticas.
KR20110009135A (ko) 2008-04-08 2011-01-27 후지필름 매뉴팩츄어링 유럽 비.브이. 복합막
JP2012528888A (ja) 2009-06-05 2012-11-15 アーシエックス セラピューティックス， インコーポレイテッド 眼科用配合剤、その製造方法およびその使用方法
CA2764473A1 (en) 2009-06-05 2010-12-09 Aciex Therapeutics, Inc. Ophthalmic formulations of fluticasone and methods of use
AU2013201465B2 (en) 2012-10-24 2016-03-03 Rayner Surgical (Ireland) Limited Stable preservative-free mydriatic and anti-inflammatory solutions for injection

Also Published As

Publication number Publication date
US8586633B2 (en) 2013-11-19
CA2493581C (en) 2014-12-23
US20140235597A1 (en) 2014-08-21
CN1684701B (zh) 2012-10-17
JP2016014055A (ja) 2016-01-28
CN101327325A (zh) 2008-12-24
JP2011006475A (ja) 2011-01-13
JP2019043965A (ja) 2019-03-22
FR15C0090I2 (fr) 2016-04-22
US9278101B2 (en) 2016-03-08
US8173707B2 (en) 2012-05-08
US20140221326A1 (en) 2014-08-07
JP2010132696A (ja) 2010-06-17
WO2004010894A3 (en) 2004-07-01
CY2015055I1 (el) 2016-06-22
EP1534313B1 (en) 2012-10-17
JP2018009033A (ja) 2018-01-18
CA2866848C (en) 2017-01-03
US9399040B2 (en) 2016-07-26
FR15C0090I1 (xx) 2016-01-22
JP2013216705A (ja) 2013-10-24
PT1534313E (pt) 2013-01-25
ES2397574T3 (es) 2013-03-08
US20040072809A1 (en) 2004-04-15
HUS1500069I1 (hu) 2016-02-29
CY2015055I2 (el) 2016-06-22
US20170100412A1 (en) 2017-04-13
JP2020169205A (ja) 2020-10-15
NL300784I1 (xx) 2015-12-30
JP2016014056A (ja) 2016-01-28
EP1534313A4 (en) 2008-06-25
SI1534313T1 (sl) 2013-03-29
US20170312295A1 (en) 2017-11-02
US20130065869A1 (en) 2013-03-14
US20130079344A1 (en) 2013-03-28
US20220175797A1 (en) 2022-06-09
AU2009248461A1 (en) 2010-01-07
JP2006504661A (ja) 2006-02-09
JP2022132495A (ja) 2022-09-08
US20100311705A1 (en) 2010-12-09
JP2022132496A (ja) 2022-09-08
WO2004010894A2 (en) 2004-02-05
LU92923I2 (fr) 2016-02-23
US20160106761A1 (en) 2016-04-21
CN1684701A (zh) 2005-10-19
NL300784I2 (nl) 2022-05-16
EP1534313A2 (en) 2005-06-01
CN103143022A (zh) 2013-06-12
AU2009248461B2 (en) 2013-07-18
HK1081455A1 (en) 2006-05-19
CA2866848A1 (en) 2004-02-05
DK1534313T3 (da) 2013-02-04
US9585895B2 (en) 2017-03-07
AU2003261304A1 (en) 2004-02-16
CA2493581A1 (en) 2004-02-05

Similar Documents

Publication Publication Date Title
BE2019C547I2 (xx)
BE2019C510I2 (xx)
BE2018C021I2 (xx)
BE2017C049I2 (xx)
BE2017C005I2 (xx)
BE2016C069I2 (xx)
BE2016C040I2 (xx)
BE2016C013I2 (xx)
BE2015C078I2 (xx)
BE2016C002I2 (xx)
BE2018C018I2 (xx)
BE2015C017I2 (xx)
BE2014C053I2 (xx)
BE2014C051I2 (xx)
BE2014C041I2 (xx)
BE2014C030I2 (xx)
BE2014C016I2 (xx)
BE2014C015I2 (xx)
BE2013C063I2 (xx)
BE2013C039I2 (xx)
BE2015C068I2 (xx)
BRPI0215435A2 (xx)
BE2013C046I2 (xx)
JP2003247937A5 (xx)
JP2003224516A5 (xx)